Literature DB >> 27763845

Prevalence of HIV infection and acceptability of point-of-care testing in a Canadian inner-city emergency department.

Rob Stenstrom1, Daphne Ling, Eric Grafstein, Rolando Barrios, Chris Sherlock, Reka Gustafson, Farzaneh Osati, Iraj Poureslami, Aslam Anis.   

Abstract

OBJECTIVES: The objective of this study was to estimate the seroprevalence of HIV infection and the acceptability of point-of-care HIV testing in an innercity Canadian emergency department.
METHODS: We conducted a prospective cohort study in an urban tertiary care emergency department between August 2009 and January 2011. Randomly selected patients were enrolled using probabilistic sampling based on patient volumes. Inclusion criteria were age 19-75 years and ability to provide informed consent. Patients who were intoxicated or in extremis were excluded. After informed consent and brief pre-test counselling, participants' HIV status was obtained using the INSTI HIV-1/HIV-2 Antibody Test. Participants completed a questionnaire on HIV risk behaviours and satisfaction with emergency department HIV testing. Participants with a positive result or those having other blood tests received confirmatory Western blot testing. HIV-positive participants were offered immediate referral to an HIV specialty clinic.
RESULTS: A total of 2,077 patients were approached, and 1,402 (67.5%) agreed to participate. Participants' mean age was 43.3 years, and 58.4% of participants were male. The HIV antibody seroprevalence based on the point-of-care test was 65/1,402 (4.6%; 95% confidence interval: 3.5%-5.8%). No new diagnoses of HIV were identified in our cohort. Patient satisfaction with point-of-care HIV testing was high (mean satisfaction score 9.6/10).
CONCLUSION: On the basis of a rapid, point-of-care HIV antibody test, the seroprevalence rate of HIV in an inner city emergency department was 4.6%. Point-of-care testing in the emergency department is acceptable, and patients' satisfaction with the testing procedure was high.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27763845      PMCID: PMC6972430          DOI: 10.17269/cjph.107.5318

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  18 in total

1.  Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time.

Authors:  B Fischer; J Rehm; T Blitz-Miller
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

Review 2.  Rapid diagnostic testing for HIV. Clinical implications.

Authors:  Sindy M Paul; Jacqueline Grimes-Dennis; Carolyn K Burr; George T DiFerdinando
Journal:  N J Med       Date:  2003-09

3.  The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004).

Authors:  Timothy R Chadborn; Valerie C Delpech; Caroline A Sabin; Katy Sinka; Barry G Evans
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

Review 4.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

5.  Treatment as prevention--a double hat-trick.

Authors:  Julio S G Montaner
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

6.  Nontargeted rapid human immunodeficiency virus screening provided by dedicated personnel does not adversely affect emergency department length of stay.

Authors:  Nathalie Coeller; Irene Kuo; Jeremy Brown
Journal:  Acad Emerg Med       Date:  2011-07-05       Impact factor: 3.451

7.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.

Authors:  Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark
Journal:  MMWR Recomm Rep       Date:  2006-09-22

8.  Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

Authors:  A David Paltiel; Milton C Weinstein; April D Kimmel; George R Seage; Elena Losina; Hong Zhang; Kenneth A Freedberg; Rochelle P Walensky
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

9.  Feasibility and success of HIV point-of-care testing in an emergency department in an urban Canadian setting.

Authors:  Marissa L Becker; Laura H Thompson; Carla Pindera; Natalie Bridger; Carmen Lopez; Yoav Keynan; Jared Bullard; Paul Van Caseele; Ken Kasper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention Guidelines: results from a high-prevalence area.

Authors:  Jeremy Brown; Robert Shesser; Gary Simon; Maria Bahn; Maggie Czarnogorski; Irene Kuo; Manya Magnus; Neal Sikka
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

View more
  3 in total

1.  Understanding barriers and facilitators to HIV testing in Canada from 2009-2019: A systematic mixed studies review.

Authors:  Claudie Laprise; Clara Bolster-Foucault
Journal:  Can Commun Dis Rep       Date:  2021-03-04

2.  Evaluation of the Utility of Point-of-Care HIV Testing on a Canadian Internal Medicine Inpatient Unit.

Authors:  Lawrence Lau; Beverly Wudel; Eugene Lee; Majid Darraj; Quinlan Richert; Adriana Trajtman; Kim Bresler; Jared Bullard; Ken Kasper; Marissa Becker; Yoav Keynan
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-11-02       Impact factor: 2.471

3.  A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review.

Authors:  Joseph Cox; Cassidy Gutner; Nadine Kronfli; Anna Lawson; Michele Robbins; Lisette Nientker; Amrita Ostawal; Tristan Barber; Davide Croce; David Hardy; Heiko Jessen; Christine Katlama; Josep Mallolas; Giuliano Rizzardini; Keith Alcorn; Michael Wohlfeiler; Eric Le Fevre
Journal:  PLoS One       Date:  2019-08-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.